Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2023-08-03
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-09-30 was 0.00%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-06-30 was 0.00%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-09-30 was 0.00%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-06-30 was 0.00%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-03 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2019-11-06 | 0.00% 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | 0.00% 10-Q · filed 2019-08-07 | 0.00% 10-Q · filed 2019-08-07 | ||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-06 | 0.00% 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-07 | 0.00% 10-Q · filed 2019-08-07 | ||
| 2017-09-30 | 0.00% 10-Q · filed 2017-11-07 | 0.00% 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2017-08-08 | 0.00% 10-Q · filed 2017-08-08 | ||
| 2017-03-31 | 0.00% 10-Q · filed 2017-05-10 | |||
| 2016-12-31 | 0.00% 10-K · filed 2017-03-07 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-07 | 0.00% 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-08 | 0.00% 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | 0.00% 10-K · filed 2017-03-07 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-14 | 0.00% 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | 0.00% 10-Q · filed 2016-09-15 | 0.00% 10-Q · filed 2016-09-15 | ||
| 2014-12-31 | 0.00% 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |